Barinthus Bio's VTP-1000 Shows Promising Safety and Dose-Dependent Effects in Phase 1 Celiac Disease Trial
核心洞察
Barinthus Bio's VTP-1000, the first antigen-specific immune tolerance therapy for celiac disease (搜索) utilizing an immunomodulator, demonstrated dose-dependent pharmacological effects and was well-tolerated with no treatment-related serious adverse events in the single ascending dose portion of its Phase 1 AVALON trial.
The trial enrolled 18 patients across three placebo-controlled cohorts, with VTP-1000 showing immune recognition without serious inflammation through observed IL-2 responses at all dose levels.
The multiple ascending dose portion of the trial, which includes a gluten (搜索) challenge, is ongoing with data expected in the second half of 2026, representing a potential breakthrough for the estimated 80 million people globally affected by celiac disease (搜索).
Barinthus Biotherapeutics has announced encouraging results from the single ascending dose (SAD) portion of its Phase 1 AVALON clinical trial evaluating VTP-1000, an investigational antigen-specific immunotherapy for celiac disease (搜索). The treatment demonstrated dose-dependent pharmacological effects and was well-tolerated across all dose levels with no treatment-related serious adverse events (SAEs).
Trial Design and Safety Results
The SAD portion of the Phase 1 AVALON trial (NCT06310291) enrolled 18 patients in three placebo-controlled cohorts of ascending doses. VTP-1000 was well tolerated at all dose levels with no treatment-related SAEs. Pharmacological data collected showed a dose-dependent effect, indicating the therapy's ability to engage the immune system in a controlled manner.
"The treatment was well-tolerated across all dose levels, with no therapy related serious adverse events," said Dr. Leon Hooftman, Chief Medical Officer of Barinthus Bio. "Importantly, the IL-2 response observed at all doses together with the safety data demonstrates immune recognition without serious inflammation."
Novel Therapeutic Approach
VTP-1000 represents the first antigen-specific immune tolerance therapy for celiac disease (搜索) to utilize an immunomodulator. The investigational injectable therapy utilizes Barinthus Bio's proprietary SNAP-TI platform to co-deliver multiple gluten (搜索)-derived peptide antigens from wheat, barley and rye proteins along with the immunomodulator rapamycin in nanoparticles designed to promote immune tolerance to gluten.
"These data from the SAD portion of the AVALON trial demonstrate the ability of a single dose of VTP-1000 to stimulate a robust targeted immune response that may minimize adverse effects associated with gluten (搜索) antigen exposure in patients with celiac disease (搜索)," said Bill Enright, Chief Executive Officer of Barinthus Bio.
Addressing Significant Unmet Medical Need
Celiac disease (搜索) affects an estimated one in 100 people of all ages, representing approximately 80 million people globally, with increasing incidence. The autoimmune condition is triggered by dietary gluten (搜索) consumption, leading to T effector cell responses that cause inflammation and damage to the small intestine's mucosal lining. This can result in rapid onset symptoms including vomiting and diarrhea, as well as long-term consequences such as malnutrition and vitamin deficiencies.
Currently, no approved treatments exist for celiac disease (搜索), leaving patients with the challenging requirement to strictly avoid consuming gluten (搜索). This dietary restriction proves difficult due to gluten's presence in many foods and cross-contamination of food production surfaces.
Next Steps and Timeline
The multiple ascending dose (MAD) portion of the trial, which includes a gluten (搜索) challenge, is ongoing with data expected in the second half of 2026. Dr. Hooftman noted that "upcoming results from multiple dosing and further immunological analysis will be critical in refining the optimal regimen and understanding the therapy's potential for true disease modification and patient benefit."
The company plans to provide detailed data, including pharmacological responses, at a scientific conference in 2026. These dose-dependent pharmacological effects represent a promising step toward developing the first therapeutic treatment for celiac disease (搜索), potentially offering patients an alternative to lifelong dietary restrictions.